Truveris, a well being expertise firm centered on decreasing prescription prices for employers and their members, introduced it has secured $15 million in Collection E funding.
Current traders Canaan Companions and New Leaf Enterprise Companions led the spherical.
what it will probably do
The corporate supplies expertise to assist employers get hold of decrease drug pricing plans. Its software program additionally permits sponsors to realize data-driven insights to scale back prescription prices, enhance pharmacy profit administration contract phrases and improve drug entry.
The funds might be used to help the corporate’s operational progress.
“There’s now unprecedented consideration on PBM practices and their influence on drug prices. For years, Truveris has been on the forefront of creating applied sciences to resolve essentially the most urgent challenges in PBM administration and value management. We, Administrators of New Leaf Enterprise Companions “We’re delighted to extend our funding in Truveris and develop our partnership to help the following chapter of the corporate’s progress,” basic supervisor Vijay Lathi mentioned in an announcement. “
market Overview
The prescription advantages firm raised $25 million in Collection D funding in 2017.
Earlier this 12 months, the corporate introduced it could promote Garrett Fienberg serves as chief working officer, Gregg DiPietro serves as chief business officer and Louise Shea serves as chief pharmacy officer.
Fienberg beforehand served as head of progress operations, DiPietro served as chief advertising and marketing officer, and Shea’s final position on the firm was senior vice chairman of product technique.
Different corporations working to scale back prescription prices embrace Drug price and telemedicine platform GoodRx, Waltz Well being, Mark Cuban Price Plus Drug Firm, Amazon, and Transcarent (a healthcare platform for self-insured employers).
